Skip to main content
. 2014 May 28;74(9):1725–1733. doi: 10.1136/annrheumdis-2013-204733

Figure 3.

Figure 3

Percentage of patients with an intensification of their disease-modifying antirheumatic drug (DMARD) therapy during the 6 months of the COmorbidities, EDucation in Rheumatoid Arthritis (COMEDRA) trial.